# US 2020/0390873 A1 · Neoantigen immunotherapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390873 A1
- Document ID: US20200390873A1
- Status: Published application
- Kind: A1
- Application number: 16/898,924
- Filed: 2020-06-11
- Published: 2020-12-17
- Earliest claimed: 2019-06-11
- Assignees: Iogenetics, LLC
- Applicants: Iogenetics, LLC
- Inventors: Jane Homan; Robert D. Bremel
- Web page: https://patentgrep.com/patent/US20200390873A1

## CPC

- A61K 39/0011: {Cancer antigens}
- G01N 33/56977: {HLA or MHC typing}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/001104: {Epidermal growth factor receptors [EGFR]}
- A61K 39/001106: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4}
- A61K 39/001151: {p53}
- A61K 39/001162: {Kinases, e.g. Raf or Src}
- A61K 39/001163: {Phosphatases}
- A61K 39/35: Allergens
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4201: {Neoantigens}
- A61K 40/4204: {Epidermal growth factor receptors [EGFR]}
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/505: {involving T-cells}
- G01N 33/6878: {in epitope analysis}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/80: {Vaccine for a specifically defined cancer}
- A61K 2039/86: {Lung}
- A61K 2039/876: {Skin, melanoma}
- A61K 2239/47: Brain; Nervous system
- A61K 2239/55: Lung
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 2333/70539: MHC-molecules, e.g. HLA-molecules
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This invention provides a method for maximizing the immune response to mutated tumor specific proteins, either by means of stimulation of dendritic cells or T cells in vitro followed by administration of these cells to a patient, or by means of administration of a neoantigen vaccine in which de novo peptides, or their encoding nucleic acids, have been designed to ensure an appropriate level of binding affinity to a particular cancer patient's WIC alleles. This invention further provides for modulating the immune response in an immunopathology other than cancer.

## Claims

### Claim 1

A method for treating cancer in a subject comprising designing a group of one or more tumor-specific T-cell stimulating peptides, or nucleic acids encoding T cell stimulating peptides, which have a desired predicted binding affinity for the MHC alleles of the subject, comprising the following steps:
obtaining a biopsy of the subject's tumor;
obtaining sequences for proteins in said biopsy;
identifying proteins from the biopsy containing mutated amino acids and the peptide comprising each of said mutated amino acids;
determining T cell exposed motifs which comprise mutated amino acids in each of the proteins;
determining the predicted binding affinity to the subject's MHC alleles of peptides which comprises each of said T cell exposed motifs, or a subset thereof;
generating an array of alternative peptides not present in the tumor, wherein each peptide in the array comprises the amino acids of one of said T cell exposed motifs, and in which one or more of the amino acids not within the T cell exposed motif are substituted to change the predicted MHC binding affinity;
selecting a group of one or more selected peptides from said array of alternative peptides which have a desired predicted binding affinity for one or more of the subject's MHC alleles; and
synthesizing said group of one or more selected peptides, or nucleic acids encoding the selected peptides.

### Claim 2 (depends on 1)

The method of claim 1 wherein said MHC alleles are MHC type I and said T cell response is a CD8+ response.

### Claim 3 (depends on 1)

The method of claim 1 wherein said MHC alleles are MHC type II and said T cell response is a CD4+ response.

### Claim 4 (depends on 1)

The method of claim 1 wherein said selected peptides are less than 20 amino acids long.

### Claim 5 (depends on 1)

The method of claim 1, wherein said group of one or more selected peptides comprises at least 5 unique peptides not present in the proteins sequenced in the tumor.

### Claim 6 (depends on 1)

The method of claim 1, wherein said desired predicted binding affinity is less than 100 nanomolar.

### Claim 7 (depends on 1)

The method of claim 1, wherein the proteins in the subject's biopsy comprise mutations that are unique to that subject.

### Claim 8 (depends on 1)

The method of claim 1, wherein the proteins in the subject's biopsy comprise mutations that are found in a multiplicity of cancers affecting a multiplicity of subjects.

### Claim 9 (depends on 1)

The method of claim 1, wherein said group of one or more selected peptides, or nucleic acids encoding the peptides, are prescribed for an identified individual patient.

### Claim 10 (depends on 1)

The method of claim 1, wherein said group of one or more selected peptides, or the nucleic acids encoding them, is administered to a subject as a vaccine.

### Claim 11 (depends on 1)

The method of claim 1, wherein said group of one or more selected peptides, or the nucleic acids that encode them, is provided to contact an antigen presenting cell in vitro and said antigen presenting cells are subsequently administered to a subject.

### Claim 12 (depends on 1)

The method of claim 1, wherein said group of one or more selected peptides is provided to stimulate T cells in vitro which are subsequently administered to a subject.

### Claim 13 (depends on 1)

A vaccine for administration to a subject with cancer comprising a group of peptides, or nucleic acids encoding the same peptides, selected according to the method of claim 1.

### Claim 14 (depends on 13)

The vaccine of claim 13, wherein said vaccination is accompanied by administration of an immunotherapy intervention

### Claim 15 (depends on 13)

The vaccine of claim 13, wherein said group of peptides or nucleic acids encoding the same peptides, is selected to stimulate T cells that target mutations unique to the particular subject.

### Claim 16 (depends on 13)

The vaccine of claim 13, wherein said group of peptides or nucleic acids encoding the same peptides, is selected to stimulate T cells that target mutations shared among a multiplicity of cancers.

### Claim 17 (depends on 13)

The vaccine of claim 13, wherein said vaccine is administered to a subject parenterally.

### Claim 18 (depends on 13)

The vaccine of claim 13, wherein said vaccine is administered to a subject intradermally.

### Claim 19 (depends on 13)

The vaccine of claim 13, wherein said group of peptides or nucleic acids encoding the same peptides, spans the deletion of exons 2-7 in EGFRviii.

### Claim 20 (depends on 13)

The vaccine of claim 13, wherein said peptides comprise the T cell exposed motifs from the group EEKKG, EKKGN, KKGNY, KGNYV, GNYVV.
